8
News
Favourable Opinion of Pharma Industry More than half of people have a favourable opinion about pharmaceutical companies operating in Ireland, according to new research from Ipsos for the Irish Pharmaceutical Healthcare Association (IPHA), the representative organisation for medicines innovators. The industry’s public favourability score, at 53%, is up from 44% since a similar poll was conducted in September 2018. When Ipsos measured sentiment towards the industry in June 2020 and in September 2021, the scores were 50% and 54%, respectively. Three in five people, or 60%, trust the industry in Ireland, almost
twice the global average measured by an Ipsos survey of people across 29 countries. More than four in five people, or 83%, believe that the industry makes an important societal and economic contribution. That figure is up slightly from 81% in 2018. Over half of people, or 55%, believe the industry focuses on what patients need. Almost nine in 10 people, or 89%, believe in the value of science in tackling unmet medical needs. More than four in five people, or 83%, believe the past five years has brought significant progress in the development
of new medicines. About the same number recognise the link between medicines and better health outcomes. Bernard Mallee, IPHA’s Director of Communications and Advocacy, said the survey shows the industry has high levels of public trust. “The public values science and the industry’s societal and economic impact. That innovator companies are spread across the regions, creating jobs and economic activity, is likely to strengthen that perspective. It is clear, too, that there is an appreciation of the positive health and quality of life impact of medicines. That the industry’s favourability rating
has improved since before the pandemic may reflect heightened public awareness of science in tackling disease. With medicines innovation moving at pace, Ireland should be ready to take advantage of the jobs and health outcomes bonus that comes with the industry. That takes planning between industry, the State and wider stakeholders. We look forward to continuing that trend,” said Mr Mallee. The next phase of Innovate For Life, the industry’s documentary campaign that tells the story of innovation in medicines, will be released in the coming weeks.
Honour for RCSI's First Female Microbiology Professor Professor Ellen Moorhouse's son and daughter pictured at the event: Dr David Moorhouse, RCSI graduate and Consultant Neurologist at Bon Secours Hospital, and Kathryn Moorhouse, RCSI Library
female Clinical Sciences Professor at RCSI with her appointment as Chair of Microbiology. She continued working at RCSI and Beaumont Hospital until her retirement in 1995. Today, Professor Moorhouse's portrait is displayed in RCSI's St Stephen's Green campus, and the Ellen Moorhouse Prize in Clinical Microbiology is awarded annually to an undergraduate medical student.
The Department of Clinical Microbiology at RCSI University of Medicine and Health Sciences has renamed its laboratory in honour of the late Professor Ellen Moorhouse. In a ceremony today at the RCSI Education and Research Centre at Beaumont Hospital, RCSI President Professor Laura Viani unveiled a plaque to mark
the official naming of the 'Ellen Moorhouse Laboratory'. Professor Ellen C. Moorhouse was born in Dublin in 1928 and studied at RCSI before working in hospitals in Ireland and England. The RCSI Department of Clinical Microbiology was opened in 1965, and in 1967 Professor Moorhouse became the first
EAHP Congress 2023
RCSI President, Professor Laura Viani, commented: "It is my great honour to unveil the plaque officially naming the Ellen Moorhouse Laboratory at the RCSI Department of Clinical Microbiology at Beaumont Hospital. In the almost 30 years that Professor Moorhouse worked at RCSI, she taught and inspired countless generations of healthcare professionals. This is a fitting tribute to the lasting impact
and influence our first female Clinical Sciences Professor has had at RCSI." For 57 years, the RCSI Department of Clinical Microbiology has been committed to educating the next generation of doctors about sepsis, healthcare-associated infection and antimicrobial resistance and improving patient care through research into the prevention and control of healthcare-associated infections and antibiotic resistance /superbugs for better health outcomes. Now led by Professor Fidelma Fitzpatrick, the team includes clinicians, other healthcare professionals and scientists, all of whom are actively involved in teaching, research, public engagement and advocacy, in addition to national health policy and health services leadership roles. Informed by its research and clinical activities, the RCSI Department of Clinical Microbiology contributes significantly to healthcare policy, national guidelines and national clinical programmes through membership of national and international committees.
The 27th Annual European Association of Hospital Pharmacists Congress will take place from 22-24 March 2023. The event will be held next year in Lisbon Congress Centre and will be entitled, ‘From Drug Design to Treatment Success – What Really Matters to Patients?’ Building on the success of previous meetings, EAHP decided to embrace new locations and a more diverse format for its in-person events, enabling the Association to host the annual congress in a new city: Lisbon. The scientific programme will encompass this wide horizon and provide an insight into these different and distinct, but also overlapping, subspecialities. I am sure that the Congress programme will effectively enable us all to grasp this rather complex landscape and to take home with us some valid answers. Find out more by visiting www.eahp.eu
AUGUST 2022 • HPN | HOSPITALPROFESSIONALNEWS.IE
